To review the current practice of retreatment with Ozurdex injections in patients with macular edema (ME) secondary to retinal vein occlusion (RVO), and to recommend simple guidelines for Ozurdex reinjection in management of RVO.
Methods
This was a multicenter retrospective study of patients who received more than 2 Ozurdex injections for the treatment of ME in RVO. Recorded parameters included percent of patients with a 15-letter gain, visual acuity (VA) improvement from baseline, change in central macular thickness (CMT), time to reinjection, and occurrence of any complications.
Results
A total of 128 patients were included, 58 (45.3%) with central RVO (CRVO) and 70 (54.7%) with branch RVO (BRVO). Mean interval for Ozurdex reinjection was 5.9 months following the first injection and 8.7 months following the second. A >15-letter gain in VA was observed in 34 (48.8%) patients with CRVO and 16 (28%) patients with BRVO. Mean overall VA improvement at month 6 did not show significance (p>0.05); however, a significantly better mean VA improvement was seen in treatment-naïve eyes (p<0.03). The CMT was significantly reduced compared to baseline. The mean CMT decreased by 214.6 μm in eyes with BRVO (n = 53) and by 355.1 μm in eyes with CRVO (n = 63) (p = 0.002). Complication rates were very low.
Conclusions
Repeated injections of Ozurdex are effective and have a favorable safety profile. In current practice, the retreatment interval with Ozurdex injections might be too long, precluding the full therapeutic potential of this treatment modality. A strategy for managing RVO patients treated with Ozurdex on an as-needed basis is provided.
HayrehS.S.. Classification of central retinal vein occlusion.Ophthalmology1983; 90: 458–74.
3.
The Branch Vein Occlusion Study Group.Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion. A randomized clinical trial.Arch Ophthalmol1986; 104: 34–41.
4.
The Central Vein Occlusion Study Group.A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion.Ophthalmology1995; 102: 1434–44.
HallerJ., BandelloF., BelfortR.Jr., Ozurdex GENEVA Study Group. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion.Ophthalmology2010; 117: 1134–46.
10.
HallerJ.A., BandelloF., BelfortR.Jr., Ozurdex GENEVA Study Group. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results.Ophthalmology2011; 118: 2453–60.
11.
SCORE Study Research Group.A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study report 6.Arch Ophthalmol2009; 127: 1115–28.
12.
SCORE Study Research Group.A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study report 5.Arch Ophthalmol2009; 127: 1101–14.
13.
KuppermannB.D., BlumenkranzM.S., HallerJ.A., Dexamethasone DDS Phase II Study Group. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema.Arch Ophthalmol2007; 125: 309–17.
14.
CampochiaroP.A., HeierJ.S., FeinerL..; BRAVO Investigators. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study.Ophthalmology2010; 117: 1102–12.
15.
BrownD.M., CampochiaroP.A., BhisitkulR.B.. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study.Ophthalmology2011; 118: 1594–602.
16.
CampochiaroP.A., BrownD.M., AwhC.C.. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study.Ophthalmology2011; 118: 2041–9.
17.
BrownD.M., CampochiaroP.A., SinghR.P., CRUISE Investigators. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study.Ophthalmology2010; 117: 1124–33.
18.
EpsteinD.L., AlgvereP.V., von WendtG., SeregardS., KvantaA.. Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve-month results of a prospective, randomized study.Ophthalmology2012; 119: 2587–91.
19.
Axer-SiegelR., DotanA., MimouniK., BorE., WeinbergerD., BourlaD.H.. Intravitreous bevacizumab treatment for macular edema due to central retinal vein occlusion.Curr Eye Res2012; 37: 818–22.
20.
SiegelR.A., DreznikA., MimouniK., BorE., WeinbergerD., BourlaD.H.. Intravitreal bevacizumab treatment for macular edema due to branch retinal vein occlusion in a clinical setting.Curr Eye Res2012; 37: 823–9.
21.
BrownD.M., HeierJ.S., ClarkW.L.. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study.Am J Ophthalmol2013; 155: 429–437.
22.
Chang-LinJ.E., AttarM., AcheampongA.A.. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant.Invest Ophthalmol Vis Sci2011; 52: 80–6.
23.
HolladayJ.T.. Proper method for calculating average visual acuity.J Refract Surg1997; 13: 388–91.
24.
Schulze-BonselK., FeltgenN., BurauH.. Visual acuities “hand motion” and “counting fingers” can be quantified with the Freiburger visual acuity test.Invest Ophthalmol Vis Sci2006; 47: 1236–40.
AugustinA.. Poster presented at the 2012 European Association for Eye and Vision Research (EVER) Congress; October 10–13; Nice, France.
27.
PommierS.. Poster presented at the 2012 EVER Congress; October 10–13; Nice, France.
28.
DodwellD.G., KrimmelD.A.. Poster presented at The Association for Research in Vision and Ophthalmology (ARVO); May 6–10 2012; Fort Lauderdale, Florida, USA.
29.
MayerW.J., WolfA., KerntM.. Twelve-month experience with Ozurdex for the treatment of macular edema associated with retinal vein occlusion.Eye Epub2013 Apr 19.
30.
MatontiF., HoffartL., BaetemanC., DenisD.. Repeated treatment for macular edema in vein occlusion by intravitreal implant of dexamethasone.Case Rep Ophthalmol2012; 3: 339–42.
31.
MoisseievE., GoldsteinM., WaisbourdM., BarakA., LoewensteinA.. Long term evaluation of the visual prognosis in patients treated with dexamethasone intravitreal implant (Ozurdex) for macular edema due to retinal vein occlusion.Eye2013; 27: 65–71.
32.
RisardS.M., PieramiciD.J., RabenaM.D.. Intravitreal ranibizumab for macular edema secondary to central retinal vein occlusion.Retina2011; 31: 1060–7.
33.
ChangL.K., SpaideR.F., KlancnikJ.M.. Longer-term outcomes of a prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion.Retina2011; 31: 821–8.
34.
HeierJ.S., CampochiaroP.A., YauL.. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial.Ophthalmology2012; 119: 802–9.
